JP2015536337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536337A5 JP2015536337A5 JP2015540784A JP2015540784A JP2015536337A5 JP 2015536337 A5 JP2015536337 A5 JP 2015536337A5 JP 2015540784 A JP2015540784 A JP 2015540784A JP 2015540784 A JP2015540784 A JP 2015540784A JP 2015536337 A5 JP2015536337 A5 JP 2015536337A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- acid molecule
- erfe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721322P | 2012-11-01 | 2012-11-01 | |
| US61/721,322 | 2012-11-01 | ||
| PCT/US2013/067771 WO2014071015A1 (en) | 2012-11-01 | 2013-10-31 | Erythroferrone and erfe polypeptides and methods of regulating iron metabolism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536337A JP2015536337A (ja) | 2015-12-21 |
| JP2015536337A5 true JP2015536337A5 (https=) | 2016-12-22 |
| JP6501362B2 JP6501362B2 (ja) | 2019-04-17 |
Family
ID=50628048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540784A Expired - Fee Related JP6501362B2 (ja) | 2012-11-01 | 2013-10-31 | エリスロフェロンおよびｅｒｆｅポリペプチドならびに鉄代謝を調節する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160122409A1 (https=) |
| EP (1) | EP2914619B1 (https=) |
| JP (1) | JP6501362B2 (https=) |
| KR (1) | KR102186218B1 (https=) |
| CN (1) | CN104854130A (https=) |
| AU (1) | AU2013337808B2 (https=) |
| BR (1) | BR112015009954A2 (https=) |
| CA (1) | CA2890040A1 (https=) |
| ES (1) | ES2731609T3 (https=) |
| RU (1) | RU2684216C2 (https=) |
| WO (1) | WO2014071015A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ748511A (en) * | 2016-04-27 | 2023-05-26 | Vladimir Badmaev | Method maintaining iron homeostasis with shogaols |
| EP3497127A1 (en) * | 2016-08-05 | 2019-06-19 | Silarus Therapeutics, Inc. | Erfe specific antibodies compositions and methods of use |
| US20200040054A1 (en) * | 2016-10-03 | 2020-02-06 | Silarus Therapeutics, Inc. | Erfe fusion polypeptides compositions and methods of use |
| NZ756975A (en) | 2017-03-13 | 2022-12-23 | Intrinsic Lifesciences Llc | Antibodies to human erythroferrone and uses thereof |
| JP7493939B2 (ja) * | 2017-05-16 | 2024-06-03 | ジェネラス バイオファーマ リミティド | 関節リウマチの治療用組成物および治療方法 |
| US11255865B2 (en) | 2017-06-06 | 2022-02-22 | The Regents Of The University Of California | Immunoassay for human erythroferrone |
| TW201945026A (zh) * | 2018-01-29 | 2019-12-01 | 美商希拉諾斯醫療公司 | 結合erfe之抗體及使用方法 |
| WO2019212364A1 (en) * | 2018-05-01 | 2019-11-07 | Christopher Joseph Pemberton | Test for heart failure |
| CA3045370A1 (en) * | 2018-06-08 | 2019-12-08 | Pfizer Inc. | Methods of treating metabolic disease |
| JP2022522265A (ja) * | 2019-01-16 | 2022-04-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エリスロフェロンの変異体及びその使用 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP2026506602A (ja) | 2023-02-13 | 2026-02-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 鉄過剰関連疾患の処置方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2359268C2 (ru) * | 2002-11-19 | 2009-06-20 | ДиАрДжи ИНТЕРНЭШНЛ, ИНК. | Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение |
| GB0423973D0 (en) * | 2004-10-28 | 2004-12-01 | Ares Trading Sa | C1q related points |
| WO2006088972A2 (en) * | 2005-02-16 | 2006-08-24 | The General Hospital Corporation | Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism |
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| GB0818273D0 (en) * | 2008-10-06 | 2008-11-12 | Cambridge Entpr Ltd | Modulation of cellular activity and differentiation |
| US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| EP2807256A4 (en) * | 2012-01-26 | 2015-10-28 | Univ Johns Hopkins | MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE |
-
2013
- 2013-10-31 ES ES13851277T patent/ES2731609T3/es active Active
- 2013-10-31 EP EP13851277.7A patent/EP2914619B1/en not_active Not-in-force
- 2013-10-31 WO PCT/US2013/067771 patent/WO2014071015A1/en not_active Ceased
- 2013-10-31 BR BR112015009954A patent/BR112015009954A2/pt not_active Application Discontinuation
- 2013-10-31 RU RU2015120601A patent/RU2684216C2/ru active
- 2013-10-31 KR KR1020157013416A patent/KR102186218B1/ko not_active Expired - Fee Related
- 2013-10-31 JP JP2015540784A patent/JP6501362B2/ja not_active Expired - Fee Related
- 2013-10-31 AU AU2013337808A patent/AU2013337808B2/en not_active Ceased
- 2013-10-31 CA CA2890040A patent/CA2890040A1/en not_active Abandoned
- 2013-10-31 CN CN201380065041.2A patent/CN104854130A/zh active Pending
-
2015
- 2015-04-28 US US14/698,608 patent/US20160122409A1/en not_active Abandoned
-
2018
- 2018-06-01 US US15/996,152 patent/US20180355008A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536337A5 (https=) | ||
| JP2013539454A5 (https=) | ||
| CN111757878A (zh) | 一种哒嗪类衍生物抑制剂、其制备方法和应用 | |
| JP2017507181A5 (https=) | ||
| WO2015073580A8 (en) | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof | |
| JP2011155981A5 (https=) | ||
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| EP2324113A4 (en) | VIRUS LIKE PARTICLES WITH COMPOUND CAPSIDAMINOIC ACID SEQUENCES FOR INCREASED CROSS-REACTIVITY | |
| HK1212711A1 (zh) | Bcma抗原結合蛋白 | |
| JP2017048194A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2017222697A5 (https=) | ||
| JP2013166763A5 (https=) | ||
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| JP2017081939A5 (https=) | ||
| JP2010524466A5 (https=) | ||
| JP2016514159A5 (https=) | ||
| JP2012517818A5 (https=) | ||
| JP2009511579A5 (https=) | ||
| MX2012000765A (es) | Dominios variables sencillos de union de albumina anti-suero mejorados. | |
| JP2014528601A5 (https=) | ||
| JP2014094951A5 (https=) | ||
| BR112012026838A2 (pt) | terapias baseadas em ligante do recptor quimiossensorial | |
| CA2818990A1 (en) | Designed repeat proteins binding to serum albumin | |
| ME02177B (me) | Supstituisani derivati ksantina |